| |
Tuesday, April 4, 2023 | 10am ET / 7am PT Life sciences leaders are reporting that investments in cloud technology are opening new doors for enhanced productivity, improved time-to-insights, and more. Join this one-hour deep dive into the latest solutions and strategies for successfully accelerating innovation while optimizing costs. Register now.
|
|
Today's Big NewsApr 17, 2023 |
|
May 1 - 3, 2023 | Jersey City, NJ Examine how the current changes to field medical will affect the role moving forward. Only a few weeks left, Register Today!
|
|
| By Nick Paul Taylor Merck & Co. is paying $10.8 billion to buy Prometheus Biosciences for its late-phase bowel disease drug candidate. Months after midphase data sent Prometheus’ stock spiraling upward, Merck has agreed to a 75% premium over the biotech’s prior closing price to land a challenger to Roivant Sciences’ RVT-3101. |
|
|
|
By Max Bayer Merck and Moderna are rapidly accelerating plans for a phase 3 trial of their cancer vaccine-Keytruda combo, hoping to launch a phase 3 trial before the end of the year. The companies found that the combination reduced the risk of recurrence or death in patients with melanoma by 44% compared to Keytruda alone. |
By James Waldron GSK revealed more details about the late-stage success of what could become the first new UTI treatment in 20 years ahead of a planned FDA filing in the coming weeks. |
Sponsored by YPrime Michael Hughes, Chief Product Officer at YPrime discusses the benefits and challenges of eConsent implementation and how to circumvent the biggest barriers to adoption. |
By Annalee Armstrong Johnson & Johnson is turning on the tap for Pipeline Therapeutics in a $50 million upfront licensing deal for an oral multiple sclerosis drug that could net the small biotech up to $1 billion down the line. |
By James Waldron Talaris Therapeutics was already put on life support back in February, when the biotech axed two kidney transplant trials along with a third of its staff. Now, the company is letting go of 95% of remaining employees. |
By Max Bayer Vaxcyte is pointing to new phase 2 data of its pneumococcal vaccine that suggests it can compete against Pfizer's Prevnar. The company is still a couple of years away from producing later-stage data, however. |
By Nick Paul Taylor Two powerhouses of the European biopharma sector are joining forces. Under a multiyear, cost-sharing alliance, argenx and Genmab are opening their suites of antibody technologies to each other to jointly go after cancer and immunology targets. |
By James Waldron Even as it searched for a saviour after a series of late-stage trial failures put Satsuma Pharmaceuticals’ future in doubt, the U.S. biotech never lost faith in the potential of its migraine spary. Now, the Japanese company behind the tech used to deliver spray has stepped in to keep the dream alive. |
By Angus Liu AstraZeneca has offered the first look at the benefit of a PD-1/L1 inhibitor when used both before and after surgery in resectable non-small cell lung cancer. But the data raise more questions than answers. |
By Andrea Park Last month, Medtronic confirmed that it had quietly combined its surgical robotics and surgical innovations operating units into a single segment, effective Feb. 1. The unit is led by Mike Marinaro, a two-decade company veteran who was previously made head of the surgical robotics business in early 2022. |
By Anastassia Gliadkovskaya CHICAGO—Amazon also announced that its latest Echo Show 15 device will soon be available for healthcare. |
By Angus Liu Roche has detailed Tecentriq’s performance in early-stage liver cancer from a positive phase 3 trial. But a negative sign of patient deaths might raise some eyebrows, and it could force the company to delay a potential FDA filing. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we talk about biotech’s top money raisers in 2022. We also cover J&J's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines. |
|
|---|
|
|
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
